Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor

Indoxyl sulfate, a protein-bound uremic toxin, leads to CKD (chronic kidney disease) progression and its complications through the activation of AhR (aryl hydrocarbon receptor) and RAS (renin-angiotensin system). Inhibition of these pathways may slow the development of CKD and CKD-associated complic...

Descripción completa

Detalles Bibliográficos
Autor principal: Akbar, Muhammad Firman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2017
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033375/
https://www.ncbi.nlm.nih.gov/pubmed/32095460
http://dx.doi.org/10.12793/tcp.2017.25.3.114
_version_ 1783499652514971648
author Akbar, Muhammad Firman
author_facet Akbar, Muhammad Firman
author_sort Akbar, Muhammad Firman
collection PubMed
description Indoxyl sulfate, a protein-bound uremic toxin, leads to CKD (chronic kidney disease) progression and its complications through the activation of AhR (aryl hydrocarbon receptor) and RAS (renin-angiotensin system). Inhibition of these pathways may slow the development of CKD and CKD-associated complications.
format Online
Article
Text
id pubmed-7033375
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Society for Clinical Pharmacology and Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-70333752020-02-24 Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor Akbar, Muhammad Firman Transl Clin Pharmacol News Indoxyl sulfate, a protein-bound uremic toxin, leads to CKD (chronic kidney disease) progression and its complications through the activation of AhR (aryl hydrocarbon receptor) and RAS (renin-angiotensin system). Inhibition of these pathways may slow the development of CKD and CKD-associated complications. Korean Society for Clinical Pharmacology and Therapeutics 2017-09 2017-09-15 /pmc/articles/PMC7033375/ /pubmed/32095460 http://dx.doi.org/10.12793/tcp.2017.25.3.114 Text en Copyright © 2017 Translational and Clinical Pharmacology http://creativecommons.org/licenses/by-nc/3.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).
spellingShingle News
Akbar, Muhammad Firman
Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
title Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
title_full Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
title_fullStr Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
title_full_unstemmed Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
title_short Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
title_sort inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033375/
https://www.ncbi.nlm.nih.gov/pubmed/32095460
http://dx.doi.org/10.12793/tcp.2017.25.3.114
work_keys_str_mv AT akbarmuhammadfirman inhibitionofindoxylsulfateinducedintrarenalreninangiotensinsystemactivationtargetingthearylhydrocarbonreceptor

Ejemplares similares